Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2020

View Archived Issues

SARS-CoV-2 requires ACE2 and TMPRSS2 for cell entry, which may be blocked by a TMPRSS2 inhibitor

Mitochondria-related miR-4485-3p is underexpressed in idiopathic asthenozoospermia

ChAdOx1 nCoV-19 vaccine candidate enters clinical testing

Oryzon to initiate phase II ESCAPE study of vafidemstat in severely ill COVID-19 patients in Spain

Promising data for COVID-19 patients with ARDS treated with remestemcel-L

MMP12 as a novel target for post-stroke neurological recovery

TNIK is a novel druggable target in LSCC with 3q amplification

Edited stem cells reverse mouse diabetes

Noncoding TET2 variants affect neurodegeneration risk

Ichnos Sciences describes new MAP4K1 inhibitors

New menin/MLL interaction inhibitors patented by University of Michigan, Agios Pharmaceuticals

Genentech, Roche present IL-2 secretion inducers

SiteOne Therapeutics identifies Nav1.7 channel blockers

Sloan-Kettering Institute for Cancer Research, Tri-I TDI identify PI3K-alpha inhibitors

Flu study links metabolic changes to cytokine storm

AGTR1 and aromatase are potential therapeutic targets in glioblastoma

SAGE-324 generally well tolerated in essential tremor patients, phase II study planned

Polyneuron receives European clearances for phase I/IIa study of PN-1007 in anti-MAG neuropathy

Lilly begins phase II study of LY-3127804 in COVID-19

Hyundai studies BPDO-1603 in phase III for moderate to severe Alzheimer's disease

Hua reports phase I data on dorzagliatin with empagliflozin in type 2 diabetes

Phase III study of Libtayo in first-line NSCLC meets OS primary endpoint

Avadel reports pivotal phase III data on FT-218 in patients with narcolepsy

New phase III trial to evaluate pacritinib in patients with severe COVID-19

Preliminary findings from phase II portion of U.S. phase II/III trial of Kevzara in COVID-19